With broader testing, more and more patients will know their status, slowing the spread of HIV and improving patient health outcomes.
More HIV+ People Can Learn Their Status
With broader screening, more and more patients will know their status, slowing the spread of HIV and improving patient health outcomes.
USPSTF Recommends HIV Screening for Adolescents and Adults Ages 15-65
The USPSTF gave an "A" rated recommendation for clinicians to screen all adolescents and adults ages 15-65 for HIV, making it an essential health benefit under the Affordable Care Act.
OraQuick ADVANCE® Webinar
The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test recently received FDA approval on new performance data which demonstrates earlier detection in seroconversion panels when compared to 3rd generation EIA. When compared with over 200 samples across 23 different seroconversion panels, the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test shows comparable results to 3rd generation automated testing, a significant improvement from the initial launch of the product in 2002. During this webinar, we will discuss the following:
The new FDA-approved performance data
Compare results from new OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test to third-generation automated EIA's
Discuss benefits of utilizing a rapid point-of-care test for HIV
Discuss benefits of the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
Register Your Testing Events
Healthcare providers, if you are planning a testing event, be sure to register it in the CDC/NPIN system to help interested patients learn about it.
Get a Testing Event Toolkit
Is your organization ready to host an HIV testing event?
Download our testing toolkit today for valuable pre-event, day-of and follow up resources that will help you make the most of your HIV initiatives.